Brief: Cns Pharmaceuticals Says University Research Confirms Active Compound In WP1122 Completely Prevents Coronavirus Replication In Vitro
April 13 (Reuters) - CNS Pharmaceuticals Inc CNSP.O :
* CNS PHARMACEUTICALS - ANNOUNCES INDEPENDENT UNIVERSITY
RESEARCH
CONFIRMS ACTIVE COMPOUND IN WP1122 COMPLETELY PREVENTS
CORONAVIRUS REPLICATION IN VITRO
* CNS PHARMACEUTICALS - WP1122 IS SUBJECT TO DEVELOPMENT
AGREEMENT
WITH WPD PHARMACEUTICALS
* CNS PHARMACEUTICALS - TO RECEIVE 50% OF NET SALES ON
RESULTING
ANTI-VIRAL COMMERCIAL PRODUCTS, INCLUDING WP1122, IN CERTAIN
INTERNATIONAL MARKETS
Source text for Eikon: ID:nPn6ZhQ2Ja
Further company coverage: CNSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on WPD Pharmaceuticals
See all newsBrief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Signs About 2 Mln Zloty Deal With WPD Pharmaceuticals
Brief: WPD Pharmaceuticals Signs Annex To License Agreement With Wake Forest University Health Sciences
Brief: WPD Pharmaceuticals Announces Proposed Restructuring Of Polish Subsidiary
Brief: WPD Pharmaceuticals Enters Into Amended And Restated Sublicense Agreement With Moleculin Biotech